Activities of Nicola CAPUTO related to 2017/2254(INI)
Plenary speeches (1)
A European One Health Action Plan against Antimicrobial Resistance (debate) IT
Amendments (85)
Amendment 4 #
Motion for a resolution
Citation 11 a (new)
Citation 11 a (new)
– having regard to the general interest paper Volume 38, Issue 1 from January 2018: "The Role of the European Food Safety Authority (EFSA) in the Fight against Antimicrobial Resistance (AMR)";
Amendment 5 #
Motion for a resolution
Citation 11 b (new)
Citation 11 b (new)
Amendment 5 #
Draft opinion
Paragraph 1
Paragraph 1
1. Stresses that antimicrobial resistance (AMR) is a critical global health issue that requires commitment and willingness of the Member States to cooperate within the EU and at the international level and a proactive, coordinated action; underlines the importance of taking a holistic approach to tackling AMR through the one-health approach, by ensuring coherence and coordination between human health, animal health and the environment;
Amendment 6 #
Motion for a resolution
Citation 13 a (new)
Citation 13 a (new)
– having regard to the proposal of a regulation of the European Parliament and of the Council on veterinary medicinal products (COM(2014)558 final)
Amendment 7 #
Motion for a resolution
Citation 14 a (new)
Citation 14 a (new)
– having regard to the January 2017, EFSA and EMA Joint Scientific Opinion on the measures to reduce the use of antimicrobials and the need to use antimicrobials in food producing animals ('RONAFA' opinion);
Amendment 9 #
Motion for a resolution
Citation 14 b (new)
Citation 14 b (new)
– having regard to the ECDC- EFSA-EMA publication which investigates the association between consumption of antimicrobials and occurrence of AMR in food-producing animals and in humans; first Joint report 2015 (JIACRA I) and second 2017 (JIACRA II);
Amendment 11 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Calls upon the Commission to support Member States in the development, assessment and implementation of national action plans against AMR, namely in what regards monitoring and surveillance systems and adequate support and incentive, taking into account the differences in reality among Member States;
Amendment 12 #
Motion for a resolution
Citation 16 a (new)
Citation 16 a (new)
– having regard to ECDC Report 2016 on Antimicrobial resistance surveillance in Europe;
Amendment 14 #
Motion for a resolution
Citation 16 b (new)
Citation 16 b (new)
– having regard to the EFSA and ECDC Scientific report from February 2018, entitled “The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2016”1a _________________ 1a http://www.efsa.europa.eu/en/press/news/ 180227
Amendment 17 #
Draft opinion
Paragraph 2
Paragraph 2
2. Calls on the Commission and the Member States to take an ambitious approach to ensuring that the targets set out in their respective Action Plans are fully and effectively achieved, and to strictly monitorAction Plans, containing measurable (clearly defined quantitative or qualitative) goals, benchmarks and effective measures to achieve these goals, are effectively implemented, and theat results thatstrictly monitored have been achieved;
Amendment 26 #
Motion for a resolution
Recital A a (new)
Recital A a (new)
Amendment 31 #
Motion for a resolution
Recital A b (new)
Recital A b (new)
Ab. whereas prudent antibiotic use and infection prevention and control in all healthcare sectors are cornerstones for effectively preventing the development and transmission of antibiotic-resistant bacteria;
Amendment 33 #
Draft opinion
Paragraph 3
Paragraph 3
3. Calls for legislative solutions that will assist farmers in reducing the need for the use of antibiotics in livestock farming, with the aim of prudent and responsible use of antimicrobialand consequently to reduce their use in livestock farming, reinforcing the obligation for a prudent and responsible use of these veterinary medicinal products; insists that such legislative solutions must address the prophylactic and metaphylactic use and the use in animals of antimicrobials that are of critical importance to human health;
Amendment 39 #
Motion for a resolution
Recital B a (new)
Recital B a (new)
Ba. whereas vaccinations and rapid diagnostic tools (RDT) have the potential to limit antibiotic abuse; whereas RDT allow healthcare professionals to quickly diagnose a patient with a bacterial or viral infection and, consequently, to reduce the misuse of antibiotics and the risk of resistance developing1a; _________________ 1aWHO Global guidelines on the prevention of surgical site infection (2016), available at: http://www.who.int/gpsc/ssi-guidelines/en/
Amendment 45 #
Motion for a resolution
Recital C
Recital C
C. whereas healthcare-associated infections (HAI) are often dueoccur due to lacking prevention measures which lead to antibiotic-resistant bacteria; whereas the European Centre for Disease Prevention and Control (ECDC) estimates that approximately 4 million patients acquire a HAI each year in the EU and that approximately 37 000 deaths result directly from these infections;
Amendment 45 #
Draft opinion
Paragraph 3 a (new)
Paragraph 3 a (new)
3a. Believes that, in order to facilitate responsible use of antimicrobials, there is an imperative need for rapid, reliable and efficacious veterinary diagnostics both to identify the cause of disease and to perform antibiotic sensitivity testing; is of the opinion that this would facilitate correct diagnosis, allow for a targeted use of antimicrobials, support using as little as possible critically important antimicrobials and, therefore, inhibit the development of antimicrobial resistance;
Amendment 48 #
Draft opinion
Paragraph 3 b (new)
Paragraph 3 b (new)
3b. Believes that the fight against antibiotic resistance should start on farms; is of the opinion that the EU should prohibit the purely preventive use of antibiotics, restrict collective treatment to very specific cases, prohibit the veterinary use of antibiotics that are critically important for human medicine and put an end to online sales of antibiotics, vaccines and psychotropic substances; takes the view that, thanks to these measures, the amounts of antibiotics found on consumers’ plates will be reduced;
Amendment 49 #
Motion for a resolution
Recital C a (new)
Recital C a (new)
Ca. whereas active screening programs with RDT have been proven to significantly contribute to the control of HAI and the reduction of the spread within hospitals and between patients1a _________________ 1aCelsus Academie voor Betaalbare zorg. Cost-effectiveness of policies to limit antimicrobial resistance in dutch healthcare organisations. Research report. January 2016. Available at: https://goo.gl/wAeN3L
Amendment 52 #
Motion for a resolution
Recital C b (new)
Recital C b (new)
Cb. whereas the use of medical devices can prevent Surgical Site Infections and therefore prevent and control the development of AMR1a; _________________ 1aWHO Global guidelines on the prevention of surgical site infection (2016), available at: http://www.who.int/gpsc/ssi-guidelines/en/
Amendment 53 #
4. Calls for further research and development into new antimicrobials and encourages alternatives to be investigated, including the development of more sustainable farming systems based on less intensive farming models, underlying the need for incentives for EU and global coordination and cooperation on research programmes in order to stimulate the development of new antimicrobials, alternative therapies and (rapid) diagnostics;
Amendment 56 #
Motion for a resolution
Recital D a (new)
Recital D a (new)
Da. whereas drug-resistant TB is the leading cause of death from AMR;
Amendment 64 #
Draft opinion
Paragraph 4 a (new)
Paragraph 4 a (new)
4a. Believes that, in order to encourage research into new antimicrobials, incentives are needed, including longer periods of protection for technical documentation on new medicines, commercial protection of innovative active substances, and protection for significant investments in data generated to improve an existing antimicrobial product or to keep it on the market;
Amendment 66 #
Motion for a resolution
Recital E a (new)
Recital E a (new)
Ea. whereas ECDC/EFSA/EMA are currently working on a joint mandate to provide outcome indicators for consumption of antimicrobials and AMR in food-producing animals and in humans;
Amendment 69 #
Draft opinion
Paragraph 4 b (new)
Paragraph 4 b (new)
4b. Highlights that significant volumes of antibiotics are used either prophylactically amongst healthy animals, to stop the development of an infection within a flock or herd, or simply for growth promotion, to speed up the pace at which animals gain weight; notes that both uses are particularly prevalent in intensive agriculture, where animals are kept in confined conditions; considers it necessary to take measures to encourage extensive grazing or organic farming methods;
Amendment 72 #
Draft opinion
Paragraph 4 c (new)
Paragraph 4 c (new)
4c. Believes that requirements to ensure that labelling makes reference to antibiotic use would improve consumer knowledge and help enable consumers to make a more informed choice; notes that having products labelled as "antibiotic- free" might also provide incentives for farmers to withhold antibiotic treatment when an animal might need it, for fear of the economic cost of not being able to sell the meat;
Amendment 76 #
Draft opinion
Paragraph 5
Paragraph 5
5. Stresses that the prevention and control of infections in animals are key to tackling AMR in agriculture and therefore disease prevention must be the first step for legislation tackling AMR in agriculture, both to, via ensureing a high standard of animal welfare and, among others, and thus reduceing the need to resort to antibiotics; emphasises that the prescription-only status for antibiotics and the accountability of professionals in the various sectors, as well as the cooperation between the veterinarian and the livestock farmers, are key factors for success; believes that antibiotics should never be used as compensation for poor hygiene or inadequate animal husbandry;
Amendment 85 #
Motion for a resolution
Paragraph 1
Paragraph 1
1. Believes that in order to take sufficient steps to tackle AMR, the One Health principle must play a central role, reflecting the fact that the health of people and animals and the environment are interconnected and that diseases are transmitted from people to animals and vice versa; stresses, therefore, that diseases have to be tackled in both people and animals, while also taking into special consideration the environment, which can be another source of resistant microorganisms;
Amendment 87 #
Motion for a resolution
Paragraph 1
Paragraph 1
1. Believes that in order to take sufficient steps to tackle AMR, the One Health principle must play a central role, reflecting the fact that the health of people and animals are interconnected and that diseases are transmitted from people to animals and vice versa; stresses, therefore, that diseases have to be tackled in both people and animals, while also taking into consideration the food chain and the environment, which can be another source of resistant microorganisms;
Amendment 91 #
Motion for a resolution
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Recalls that the often-cited figure of 25.000 deaths in Europe and related costs of over 1,5 Billion euros owing to AMR dates back to 2007 and that continuously updated information on the real burden of AMR is necessary;
Amendment 97 #
Draft opinion
Paragraph 7
Paragraph 7
7. Emphasises the crucial role of education and training programmes in raising awareness about antimicrobial resistance and the prudent use of antimicrobials in veterinary medicine for farmers and, veterinarians, professionals, and all those involved in livestock farming;
Amendment 109 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Stresses that the appropriate and prudent use of antimicrobials is essential to limiting the emergence of AMR in human healthcare, animal husbandry and aquaculture; stresses that there are considerable differences in the way Member States handle and address AMR; calls on the Commission to consider mandatory routine collection and submission of monitoring data at EU level and to establish indictors to measure progress in the fight against AMR in all One Health domains at EU level;
Amendment 111 #
Draft opinion
Paragraph 8
Paragraph 8
Amendment 120 #
Motion for a resolution
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Calls on the Commission to establish indicators to measure and compare progress in the fight against AMR and to encourage the evaluation of the standardized data;
Amendment 121 #
Draft opinion
Paragraph 8 a (new)
Paragraph 8 a (new)
8a. Stresses that more cooperation between Member States, the Commission and the pharmaceutical industry is crucial in order to keep existing effective antimicrobials used in human and veterinary medicine on the market, explore alternative solutions to ensure availability of these antimicrobials on the market and promote its responsible use as well as preventive measures;
Amendment 123 #
Motion for a resolution
Paragraph 2 b (new)
Paragraph 2 b (new)
2b. Stresses the need for a time frame embedding the European One Health Action Plan; calls on the Commission and the Member States to include measurable and time-bound objectives and targets in the European One Health Action Plan and in national action plans to enable benchmarking;
Amendment 125 #
Motion for a resolution
Paragraph 2 c (new)
Paragraph 2 c (new)
2c. Calls on the Commission to coordinate and monitor national strategies to enable sharing of best practices between Member States;
Amendment 127 #
Motion for a resolution
Paragraph 2 d (new)
Paragraph 2 d (new)
2d. Calls on the Commission to consider including antibiotics use reduction in food producing animals as an objective under the Common Agricultural Policy (CAP), and ensuring effective ways of using the resources distributed under the CAP to contribute to national actions plans;
Amendment 130 #
Motion for a resolution
Paragraph 2 e (new)
Paragraph 2 e (new)
2e. Calls on the Commission to conduct and publish amid-term evaluation and ex-post evaluation of the One Health Action Plan and to involve all relevant stakeholders in the evaluation procedure;
Amendment 135 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Calls on the Commission and the Member States to align surveillance, monitoring and reporting of AMR patterns and pathogens; calls on the Commission to draft, in consultation with EMA, EFSA, ECDC and other key stakeholders, an EU priority pathogen list (PPL) for both humans and animals, thereby clearly setting future R&D priorities;
Amendment 137 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Calls on the Commission and the Member States to align surveillance, monitoring and reporting of AMR patterns and pathogens; calls on the Commission to encourage and support Member States to put in place and monitor national targets for the surveillance and reduction of AMR/HAIs;
Amendment 141 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Calls on the Commission and the Member States to align surveillance, monitoring and reporting of AMR patterns and pathogens and to encourage amore holistic data collection;
Amendment 141 #
Draft opinion
Paragraph 10
Paragraph 10
10. Stresses that awareness of the issue should be raised at the highest political level, involving all Heads of State and all relevant UN and international organizations and aim for compromises and ambitious outcomes; emphasises that international cooperation involving sharing information, knowledge and best practices in tackling AMR is crucial in the context of the one- health approach for the benefit of human and animal health globally.;
Amendment 156 #
Motion for a resolution
Paragraph 5
Paragraph 5
5. Urges the Commission to expand the role and funding of the ECDC, EFSA and EMA in the fight against AMR; believes that close collaboration between these EU agencies is paramount;
Amendment 159 #
Motion for a resolution
Paragraph 5
Paragraph 5
5. Urges the Commission to expand the role and funding of the ECDC in the fight against AMR and HAI;
Amendment 169 #
Motion for a resolution
Paragraph 6
Paragraph 6
6. Emphasises that infection prevention, biosecurity measures, active screening programs, and control practices are critical in the control of all infectious microorganisms as they reduce the need for antimicrobials and consequently opportunities for microorganisms to develop and spread resistance;
Amendment 172 #
6a. Stresses that compliance to infection control guidelines, integrating targets for infection rate reductions and supporting best practice all help address patient safety in the hospital environment;
Amendment 176 #
Motion for a resolution
Paragraph 6 b (new)
Paragraph 6 b (new)
6b. Encourages Member States to prevent the spread of infection by resistant bacteria by implementing active screening programs with rapid diagnostic technologies in order to quickly identify patients infected with multi-drug resistant bacteria and to put in place appropriate infection control measures (e.g. patient isolation, cohorting and reinforced hygiene measures);
Amendment 188 #
Motion for a resolution
Paragraph 7 a (new)
Paragraph 7 a (new)
7a. Highlights that preventive measures, including hygiene, should be scaled up to reduce the amount of antibiotics currently required to treat infections and medical procedures; notes that awareness on the perils of self- medication and overprescription should be a core component of this preventive strategy, and deprescription by health care professionals a possible solution;
Amendment 193 #
Motion for a resolution
Paragraph 8
Paragraph 8
8. Urges the Commission and Member States to create harmonised quality standards in EU-wide curriculafollowing the One Health approach in EU-wide curricula, to foster interdisciplinary education and proper stewardship for health professionals in relation to prescribing, dosage, use, and disposal of antimicrobials and AMR contaminated materials;
Amendment 196 #
Motion for a resolution
Paragraph 8
Paragraph 8
8. Urges the Commission and Member States to create harmonised quality standards in EU-wide curricula and proper stewardship for health professionals in relation to prescribing, dosage, use and disposal of antimicrobials; , and to ensure the establishment and deployment of multidisciplinary antibiotic stewardship teams in hospital settings;
Amendment 200 #
Motion for a resolution
Paragraph 8 a (new)
Paragraph 8 a (new)
8a. Highlights the need for the development of protocols for prescription and use of antibiotics at a EU level; asks also for the compulsory collection, at a national level, of all prescriptions of antibiotics;
Amendment 204 #
Motion for a resolution
Paragraph 9
Paragraph 9
9. Is aware that health professionals often need to make quick decisions on therapeutic indication for antibiotic treatment; notes that rapid diagnostic tests can help to support theseffective and accurate decisions-making;
Amendment 238 #
Motion for a resolution
Paragraph 11
Paragraph 11
11. Calls on the Commission and the Member States to restrict or stop the sale of antibiotics by those doctors or veterinarians who also prescribe them, and to remove incentives for doctors and veterinarians to prescribe antibiotics;
Amendment 243 #
Motion for a resolution
Paragraph 11 a (new)
Paragraph 11 a (new)
11 a. Recommends that the newly- created “One Health Network”, as well as the EU Joint Action on AMR and Healthcare-Associated Infections (EU- JAMRAI) should also involve other key relevant stakeholders apart from member states;
Amendment 252 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Highlights the value of vaccines in combating AMR; recommends integration of targets for life-long vaccination in the population, particularly in vulnerable groups, as a key element of national action plans on AMR;
Amendment 263 #
Motion for a resolution
Paragraph 12 a (new)
Paragraph 12 a (new)
12 a. Calls on the European Commission to explore how best to leverage the potential of the European Reference Networks for rare diseases and to assess their possible role in AMR research;
Amendment 269 #
Motion for a resolution
Paragraph 13
Paragraph 13
13. Highlights that the pollution of the environment by human and veterinary antibiotic residues is an emerging problem and encourages further research into the relative impact of this pollution on AMR that requires coherent policy measures to avoid the spreading of AMR between ecosystems, animals and people; believes that further research into transmission dynamics and the relative impact of this pollution on AMR is required;
Amendment 279 #
Motion for a resolution
Paragraph 13 a (new)
Paragraph 13 a (new)
13 a. Stresses that release of pharmaceuticals into the environment is an important factor in the emergence of AMR both on a European and an international level;
Amendment 280 #
Motion for a resolution
Paragraph 13 a (new)
Paragraph 13 a (new)
13 a. Urges the Commission to effectively deploy available legislation in all AMR-related areas to ensure that the threat is being tackled in all policies;
Amendment 283 #
Motion for a resolution
Paragraph 13 b (new)
Paragraph 13 b (new)
13 b. Calls on the Commission to appropriately address the release of pharmaceuticals into the environment and the emergence of AMR in its strategic approach to pharmaceuticals in the environment;
Amendment 290 #
Motion for a resolution
Paragraph 14
Paragraph 14
14. Calls for environmental risk assessments as part of the marketing authorisation process for antimicrobials as well as for older products already on the market;
Amendment 297 #
Motion for a resolution
Paragraph 14 a (new)
Paragraph 14 a (new)
14 a. Calls on the Commission to ensure that aspects of environmental protection related to antibiotic products fall within the scope of the EU Good Manufacturing Practices (GMP) to address the release of antibiotics into the environment;
Amendment 302 #
Motion for a resolution
Paragraph 14 a (new)
Paragraph 14 a (new)
14 a. Urges the Commission to formally include civil society in One Health discussions, for example by setting up and funding a dedicated stakeholder network;
Amendment 305 #
Motion for a resolution
Paragraph 14 b (new)
Paragraph 14 b (new)
14 b. Calls on the Commission and Member States to revise their Codes of Good Agricultural Practice and revise relevant best available techniques under the Industrial Emissions Directive (IED) to include provisions for the handling of manure containing antibiotics/AMR microorganisms;
Amendment 311 #
Motion for a resolution
Paragraph 14 c (new)
Paragraph 14 c (new)
14 c. Calls on the Commission to review and revise Best Available Techniques Reference (BREF) documents under the Industrial Emissions Directive (IED) relevant to emissions from the manufacturing plants of antibiotics;
Amendment 312 #
Motion for a resolution
Paragraph 14 d (new)
Paragraph 14 d (new)
14 d. Calls on the Commission to include pharmaceuticals in the watch lists for monitoring surface and groundwater under the Water Framework Directive (WFD) along with AMR in relevant microorganisms;
Amendment 317 #
Motion for a resolution
Paragraph 14 e (new)
Paragraph 14 e (new)
14 e. Calls on the Commission and Member States to ensure that environmental issues are introduced into the pharmacovigilance system for human pharmaceuticals and strengthened for veterinary pharmaceuticals particularly in relation to AMR;
Amendment 318 #
Motion for a resolution
Paragraph 14 f (new)
Paragraph 14 f (new)
14 f. Calls on the Commission and Member States to set quality standards (threshold values) or risk assessment requirements to ensure that the concentrations of relevant antibiotics and AMR microorganisms in manure, sewage sludge and irrigation water are safe before they can be spread on agricultural fields;
Amendment 321 #
Motion for a resolution
Paragraph 15 a (new)
Paragraph 15 a (new)
15 a. Welcomes that EFSA and EMA recently reviewed and discussed a number of alternatives to the use of antimicrobials in food-producing animals, some of which have been shown to yield promising results in the improvement of animal health parameters during experimental studies; recommends therefore to give new impetus to scientific research on alternatives and design an EU legislative framework that would stimulate their development and clarify the pathway for their approval;
Amendment 328 #
Motion for a resolution
Paragraph 16
Paragraph 16
16. Welcomes recent research projects into alternative antibiotic therapies such as bacteriophage therapy, such as the EU- funded Phagoburn project; notes that no bacteriophage therapies have been authorised at EU level so far; calls on the Commission to propose a legislative framework for bacteriophage therapy;
Amendment 337 #
Motion for a resolution
Paragraph 17
Paragraph 17
17. Encourages the European Medicines Agency (EMA) in collaboration with EFSA and ECDC to review all available information on the benefits and risks of older antimicrobial agents and to consider whether any changes to their approved uses are required;
Amendment 345 #
Motion for a resolution
Paragraph 18
Paragraph 18
18. Calls on the Commission to increase funding for early research in epidemiology and immunology of AMR pathogens, in particular the pathways of transmission between animals and humans and the environment;
Amendment 347 #
Motion for a resolution
Paragraph 18 a (new)
Paragraph 18 a (new)
18 a. Welcomes recent cross-border research projects into antimicrobial stewardship and the prevention of infection, such as the EU-funded i-4-1- Health Interreg project; calls on the Commission to increase research funding for measures to prevent healthcare- associated infections (HAI);
Amendment 350 #
Motion for a resolution
Paragraph 18 b (new)
Paragraph 18 b (new)
18 b. Calls on the Commission to further support its R&D effort on AMR, including global health infections defined in the Sustainable Development Goals, especially drug resistant TB as well as Malaria, HIV and NTDs, as part of the next EU Research Framework Programme, including by dedicating a specific mission in the Programme to the global fight against AMR;
Amendment 364 #
Motion for a resolution
Paragraph 21
Paragraph 21
21. Calls on the Commission and the Member States to support the implementation of new economic models, pilot projects and incentives to boost the development of new diagnostics, antibiotics, alternatives to using antimicrobials, medical devices, and vaccines;
Amendment 367 #
Motion for a resolution
Paragraph 21
Paragraph 21
21. Calls on the Commission and the Member States to support the implementation of new economic models, pilot projects and pull and push incentives to boost the development of new diagnostics, antibiotics, alternatives and vaccines;
Amendment 389 #
Motion for a resolution
Paragraph 23
Paragraph 23
23. Calls on the Commission and Member States to develop new incentive models that delink payment from prescribing volume, , as excess prescription has been directly linked to a rise in AMR;
Amendment 392 #
Motion for a resolution
Paragraph 23 a (new)
Paragraph 23 a (new)
23 a. Acknowledges the key role of pharmacists in raising awareness around the appropriate use of antimicrobials, as well as in the prevention of AMR; encourages Member States to expand their responsibilities by allowing exact quantity dispensing and enabling the administration of certain vaccines and rapid diagnostic tests within pharmacies;
Amendment 402 #
Motion for a resolution
Paragraph 24
Paragraph 24
24. Recalls that owing to the complexity of the problem, its cross-border dimension, the severe consequences for human and animal health and the environment, as well as the high economic burden, AMR requires urgent and coordinated global and intersectoral action;
Amendment 412 #
Motion for a resolution
Paragraph 25 a (new)
Paragraph 25 a (new)
25 a. Welcomes the WHO Global Action Plan (GAP) on AMR, which was adopted unanimously in May 2015 by the 68th World Health Assembly; stresses the need for global, European and national action plans to be in line;
Amendment 437 #
Motion for a resolution
Paragraph 28
Paragraph 28
28. Calls on the Commission and the Member States to strengthen measures to combat illegal practices related to the trade and use of antimicrobialproduction, trade, use and disposal of antimicrobials; emphasizes that actors involved in the life-cycle chain of antimicrobials need to take the responsibility for their actions;
Amendment 441 #
Motion for a resolution
Paragraph 28 a (new)
Paragraph 28 a (new)
28 a. Notes the importance of universal access to existing antibiotics, in order to ensure targeted treatment with specific antibiotics, which should be available in order to avoid the misuse of unsuitable antibiotics and the overuse of broad- spectrum antibiotics;
Amendment 443 #
Motion for a resolution
Paragraph 28 b (new)
Paragraph 28 b (new)
28 b. Calls on the Commission to take the global lead in advocating for evidence-based best practice models for early diagnosis to tackle AMR;
Amendment 445 #
Motion for a resolution
Paragraph 29
Paragraph 29
29. Calls on the Commission to work towards continued high-level political attention and commitment to AMR action, including in UN forums, the G7 and the G20; highlights the opportunity for European scientific bodies, like ECDC, to take global stewardship roles;
Amendment 449 #
Motion for a resolution
Paragraph 29 a (new)
Paragraph 29 a (new)
29 a. Calls on the Commission to advocate collaboration between the EU and international organisations, including WHO, FAO, and OIE;